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Dengue fever emerged in Bangladesh in 2000. We
tested 225 serum samples from febrile patients and 184
blood donors in 1996 and 1997 for dengue antibodies; 55
(24.4%) febrile patients had dengue antibodies (65.5% with
secondary infection pattern), compared with one (0.54%)
donor (p < 0.001), suggesting that dengue transmission
was ongoing well before 1996. 
D
engue continues to spread globally; two fifths of the
global population is at risk, primarily within tropical
countries (1,2). A proportion of dengue infections result in
dengue hemorrhagic fever (DHF), which is associated with
high death rates. Most deaths are preventable with timely,
careful fluid management. In areas hyperendemic for
dengue with clinicians experienced in diagnosis and man-
agement of dengue fever and DHF, death rates are relative-
ly low (3,4). Recognition of ongoing dengue transmission
is helpful for optimal management and implementation of
rational prevention programs (5).
While dengue viruses were likely responsible for what
was called Dhaka fever in 1965 (6), dengue fever and DHF
were not recognized in recent decades in Bangladesh, until
an outbreak occurred in 2000 (7). Nearly 15,000 patients
have been hospitalized in Dhaka and other urban areas in
Bangladesh since 2000. News reports focus daily on the
numbers of new dengue cases, and panic is palpable
among residents of Dhaka. We assisted the Government of
Bangladesh in designing and implementing emergency
strategies to contain the epidemic. Serologic responses of
dengue patients (based on evaluating immunoglobulin [Ig]
M/IgG ratios) identified during surveillance showed that
approximately 70% of patients had also been infected with
dengue previously (7), suggesting that unrecognized
dengue illnesses had been present. 
The objective of this study was to evaluate whether
undiagnosed dengue infection was occurring in
Bangladesh before 2000. We studied stored serum samples
from a group of febrile patients who attended the Clinical
Laboratory of ICDDR,B during 1996 and 1997 and who
were evaluated for typhoid. 
Materials and Methods
Acute-phase serum specimens, which had been submit-
ted for Widal testing for evaluation of typhoid fever, were
identified from 225 febrile patients who attended the
Clinical Laboratory of ICDDR,B during 1996 and 1997;
specimens were stored at –20°C. We also identified serum
samples from 184 blood donors obtained during the same
interval and stored under similar conditions. Information
about age and sex were not available for blood donors. All
409 serum specimens were tested for antibodies to dengue
viruses and Japanese encephalitis virus (JEV) by IgM and
IgG antibody–capture enzyme linked immunoassay (8,9). 
Microtiter plates were coated with 100 µL goat antihu-
man IgM and IgG antibodies and incubated at 4°C for 48
to 72 h. Four coated plates were kept at room temperature
for half an hour and washed five times with PBS-T (phos-
phate-buffered saline); 50 µLof diluted patient serum sam-
ples and positive and negative controls (1:100) were added
into respective wells and incubated at 4°C overnight in a
moisture box. After the plates were washed five times with
PBS-T, 50 µL pooled antigens of dengue virus (DENV)-
1–4 and 50 µL JEV were each added to separate wells and
incubated at room temperature for 2 h. After the plates
were washed five additional times to remove excess anti-
gens with PBS-T, 25 µL working conjugate was added to
each well and incubated at 37°C for 1 h. After the plates
were washed with PBS-T five times to remove excess con-
jugate and PBS x  10 twice, 100 µL ortho-phenylenedi-
amine (OPD) solution was added to each well and incubat-
ed at room temperature for 30 min. Finally, 50 µL stop
solution (1 M sulfuric acid) was added to each well. An
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optical density (OD) at 492 nm. 
OD values were used to calculate binding index and
units of IgM and IgG. Binding index was defined as OD of
test sample minus OD of negative control divided by OD
of weak positive control (defined as 100 U) minus OD of
the negative control. We multiplied binding index by 100
to obtain units of respective antibodies. Borderline results
(±5 of 40 U) were repeated for validation. 
IgM and IgG antibody values of >40 U were considered
positive for dengue or JEV. When anti-dengue IgM or IgG
values were >40 U, primary infection (first-time exposure)
was defined as a ratio of IgM to IgG >1.8 and secondary
infection (>1 previous exposure) was defined as a ratio of
<1.8 (10).
Widal test was performed by rapid slide titration tech-
nique, as described by the manufacturer (Murex Biotech
Ltd, Dartford, UK). A single test was performed on all
acute-phase serum. Atest was defined as positive when the
titer was >1:80. However, recognizing the nonspecificity
of this break point, we also considered titers of >1:320 or
fourfold rise in serum antibody between acute- and conva-
lescent-phase serum samples as representing “likely
typhoid” (11).
Results
Among 225 febrile patients, 123 (54.7%) were male
(Table 1). More than half (52.9%) of the patients were <15
years of age; most of the other patients were young adults
<30 years old (32.9%). 
Fifty-five (24.4%) febrile patients had dengue antibod-
ies, including 9 with antibodies reacting with JEV anti-
gens; no dengue-negative serum samples reacted with JEV,
suggesting that JEV antibody responses represented fla-
vivirus cross-reaction (ratio of anti-dengue IgM units to
anti-Japanese encephalitis IgM units were >1.0 in all 9)
(9). In contrast, among 184 blood donors, one (0.54%) had
measurable dengue antibodies (p < 0.001 when compared
with febrile patients); none had JEV antibodies. 
The male (22%) to female (27.5%) proportion of those
positive for dengue antibodies was similar (Table 2).
Among the 55 febrile patients with evidence of dengue
infection, 36 (65.5%) had secondary antibody patterns, and
19 (34.5%) patients had primary patterns. Among those
with dengue, secondary pattern was more common in
female persons (75%) than in male persons (55.6%; p =
0.1). While not statistically significant, children <15 years
old were more likely to have a primary pattern (12 [44.4%]
of 27) when compared with people >15 years old (7 [25%]
of 28).
Widal test results were positive (1:80 dilution) in 52
(23.1%) serum samples from febrile patients. Widal test
results did not correlate (negatively or positively) with
dengue test results; 15 (28.8%) of 52 Widal-positive serum
samples had evidence of dengue antibodies compared with
40 (23.1%) of 173 Widal-negative serum samples. When a
stricter definition (>1:320 dilution) for a positive Widal
test result was used, 3 (16.7%) of 18 positive serum sam-
ples had dengue antibodies compared with 52 (25.1%) of
207 negative serum samples (p > 0.5). 
A substantial proportion (47.1%) of febrile patients
were seen during July and August (Figure). Among 169
febrile patients during the rainy season and brief postrainy
season (May-November, which mirrored the dengue sea-
son in Bangladesh during the years 2000 and 2001), 49
(29%) were positive for dengue compared with 6 (10.7%)
of 56 febrile patients who were ill during December to
April (p < 0.01). 
Discussion
Except for an epidemic in 1965 (6) and some isolated
subsequent reports (12,13), dengue infection was not recog-
nized as an important cause of illness in Bangladesh until
2000. The finding that febrile patients, but not blood donors
from Dhaka from the same period, had dengue antibodies
suggests that many of the febrile illnesses we evaluated in
1996 were caused by dengue, 4 years before the epidemic
dengue was documented. Furthermore, most patients with
dengue infection had antibody patterns consistent with pre-
vious infection, suggesting that dengue transmission had
been ongoing well before 1996. Dengue illness was unrec-
ognized most likely because it often is a self-limited
influenzalike illness; more severe forms of dengue are con-
fused with other illnesses prevalent in this tropical, impov-
erished, and densely populated, developing country. 
While febrile patients described in this report were
being evaluated for typhoid fever, it appears that they were
actually more likely to have dengue. This finding under-
scores a need for access to diagnostic assays to confirm or
broaden clinical suspicion. Diseases like dengue, typhoid,
leptospirosis, and influenza, among others, may have signs
and symptoms that are clinically indistinguishable. In
some circumstances, laboratory confirmation can influ-
ence management and clinical outcome for the patient, as
well as implementation of public health measures for pre-
vention and control.
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Table 1. Age and sex distribution of 225 serum samples of 
febrile patients who attended the clinical laboratory of ICDDR,B, 
1996–1997 
Age group  Male, no. (%)  Female, no. (%)  Total 
<5  21 (17.1)  19 (18.6)  40 (17.8) 
5–15  46 (37.4)  33 (32.4)  79 (35.1) 
16–29  38 (30.9)  36 (35.3)  74 (32.9) 
>30  18 (14.6)  14(13.7)  32 (14.2) 
Total  123 (54.7)
a  102 (45.3)
a  225 (100) 
aTotals represent row percentages; all others are column percentages. 
 The Widal test is an imperfect test for typhoid, though
specificity improves somewhat with rising titers (14). We
did not observe such increases in specificity for typhoid,
based on the proportion of patients with various Widal
titers who had dengue antibodies. Some febrile patients
may have had nonspecific stimulation of antibodies to O-
antigens of enteric bacterial commensals resulting in false
positive Widal tests (11). However, the possibility of con-
comitant infection caused by dengue and typhoid cannot
be ruled out for some of these patients, given the exceed-
ingly high incidence of typhoid in this region (15). 
A widely held contention is that preexisting antibodies
to dengue following previous exposure to the virus may
predispose patients to more severe dengue illnesses, such
as DHF and dengue shock syndrome because of antibody-
dependent enhancement (1). In Bangladesh, thus far, only
dengue serotypes 2 and 3 have been identified (7). Our
findings suggest that, despite recent recognition of dengue
illnesses in Bangladesh, previous exposure is not uncom-
mon. We cannot be certain that DHF was also prevalent
well before 2000, since comprehensive medical records
needed for retrospective case identification are not avail-
able. However, if we assume that the antibody-dependent
enhancement-risk hypothesis is correct, earlier dengue
transmission within Bangladesh may be responsible for
DHF cases now being observed and perhaps represents a
substantial risk for greater incidence of DHF in the future,
if new dengue serotypes are introduced. 
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